PT - JOURNAL ARTICLE AU - McCarthy, Matthew W. AU - Naggie, Susanna AU - Boulware, David R. AU - Lindsell, Christopher J. AU - Stewart, Thomas G. AU - Felker, G. Michael AU - Jayaweera, Dushyantha AU - Sulkowski, Mark AU - Gentile, Nina AU - Bramante, Carolyn AU - Singh, Upinder AU - Dolor, Rowena J. AU - Ruiz-Unger, Juan AU - Wilson, Sybil AU - DeLong, Allison AU - Remaly, April AU - Wilder, Rhonda AU - Collins, Sean AU - Dunsmore, Sarah E. AU - Adam, Stacey J. AU - Thicklin, Florence AU - Hanna, George AU - Ginde, Adit A. AU - Castro, Mario AU - McTigue, Kathleen AU - Shenkman, Elizabeth AU - Hernandez, Adrian F. AU - , TI - Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial AID - 10.1101/2022.10.17.22281178 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.17.22281178 4099 - http://medrxiv.org/content/early/2022/11/01/2022.10.17.22281178.short 4100 - http://medrxiv.org/content/early/2022/11/01/2022.10.17.22281178.full AB - Background The effectiveness of fluvoxamine to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic coronavirus disease 2019 (COVID-19) is unclear.Design ACTIV-6 is an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial testing repurposed medications in outpatients with mild to moderate COVID-19. A total of 1288 non-hospitalized adults aged ≥30 years with confirmed COVID-19 experiencing ≥2 symptoms of acute infection for ≤7 days prior to randomization were randomized to receive fluvoxamine 50 mg or placebo twice daily for 10 days. The primary outcome was time to sustained recovery, defined as the third of 3 consecutive days without symptoms. Secondary outcomes included composites of hospitalization or death with or without urgent or emergency care visit by day 28.Results Of 1331 participants randomized (mean [SD] age, 48.5 [12.8] years; 57% women; 67% reported receiving at least 2 doses of a SARS-CoV-2 vaccine), 1288 completed the trial (n=614 placebo, n=674 fluvoxamine). Median time to recovery was 13 days (IQR 12–13) in the placebo group and 12 days (IQR 11–14) in the fluvoxamine group (hazard ratio [HR] 0.96, 95% credible interval [CrI] 0.86–1.07; posterior probability for benefit [HR>1]=0.22). Twenty-six participants (3.9%) in the fluvoxamine group were hospitalized or had urgent or emergency care visits compared with 23 (3.8%) in the placebo group (HR 1.1, 95% CrI 0.6–1.8; posterior probability for benefit [HR<1]=0.340). One participant in the fluvoxamine group and 2 in the placebo group were hospitalized; no deaths occurred. Adverse events were uncommon in both groups.Conclusions Treatment with fluvoxamine 50 mg twice daily for 10 days did not improve time to recovery, compared with placebo, among outpatients with mild to moderate COVID-19. These findings do not support the use of fluvoxamine at this dose and duration in patients with mild to moderate COVID-19.Competing Interest StatementCompeting interests for all authors are provided in the manuscript.Clinical TrialNCT04885530Funding StatementACTIV-6 is funded by the National Center for 10 Advancing Translational Sciences (NCATS) (3U24TR001608-06S1). Additional support for this study was provided by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (contract No.75A50122C00037). The Vanderbilt University Medical Center Clinical and Translational Science Award from NCATS (UL1TR002243) supported the REDCap infrastructure. Additional support was provided by the Vanderbilt University Medical Center Recruitment Innovation Core (U24TR001579).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPrior to deposition of the data in a public repository which will occur when the platform trial has concluded, persons may request the data by submitting a proposal. If the data can be used for the proposed purpose and it is consistent with the informed consent, then the data will be released under a Data Use Agreement.